Surgery Partners, Inc. (NASDAQ:SGRY – Get Rating) insider George Goodwin sold 25,525 shares of the business’s stock in a transaction on Thursday, April 21st. The stock was sold at an average price of $62.58, for a total value of $1,597,354.50. Following the transaction, the insider now owns 57,990 shares of the company’s stock, valued at approximately $3,629,014.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
George Goodwin also recently made the following trade(s):
- On Thursday, March 17th, George Goodwin sold 10,931 shares of Surgery Partners stock. The stock was sold at an average price of $53.68, for a total value of $586,776.08.
- On Monday, February 28th, George Goodwin sold 3,777 shares of Surgery Partners stock. The shares were sold at an average price of $52.23, for a total value of $197,272.71.
NASDAQ:SGRY traded up $2.21 during trading hours on Monday, hitting $52.33. 682,736 shares of the company’s stock traded hands, compared to its average volume of 399,020. The stock has a market cap of $4.70 billion, a price-to-earnings ratio of -43.73, a P/E/G ratio of 5.27 and a beta of 2.89. Surgery Partners, Inc. has a twelve month low of $37.63 and a twelve month high of $69.58. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.65 and a current ratio of 1.76. The stock has a fifty day moving average price of $53.16.
Several analysts have recently weighed in on the company. SVB Leerink upped their price objective on Surgery Partners from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Wednesday, March 2nd. StockNews.com raised Surgery Partners from a “sell” rating to a “hold” rating in a report on Tuesday, March 29th. Royal Bank of Canada reduced their target price on Surgery Partners from $70.00 to $65.00 and set an “outperform” rating for the company in a report on Tuesday, March 1st. Zacks Investment Research lowered Surgery Partners from a “buy” rating to a “hold” rating in a research report on Wednesday, March 2nd. Finally, JPMorgan Chase & Co. upped their price target on Surgery Partners from $50.00 to $55.00 and gave the company a “neutral” rating in a research report on Wednesday, March 2nd. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Surgery Partners presently has an average rating of “Buy” and a consensus target price of $57.86.
Hedge funds have recently modified their holdings of the business. Signaturefd LLC acquired a new position in Surgery Partners in the 4th quarter worth about $63,000. Nisa Investment Advisors LLC increased its holdings in shares of Surgery Partners by 444.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,960 shares of the company’s stock valued at $84,000 after acquiring an additional 1,600 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Surgery Partners during the 4th quarter valued at about $92,000. Balyasny Asset Management LLC acquired a new position in shares of Surgery Partners during the 3rd quarter valued at about $203,000. Finally, Squarepoint Ops LLC increased its holdings in shares of Surgery Partners by 8.6% during the 3rd quarter. Squarepoint Ops LLC now owns 4,943 shares of the company’s stock valued at $209,000 after acquiring an additional 390 shares during the last quarter.
Surgery Partners Company Profile (Get Rating)
Surgery Partners, Inc, through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.
- Get a free copy of the StockNews.com research report on Surgery Partners (SGRY)
- Hasbro Insider Bets Big On Stock Rebound
- The Coca-Cola Company Gets KO’d After Stunning Quarter
- Schwab Stock Can Be Caught Down Here
- Snap Up Some Snap-On On Post-Earnings Weakness
- Time to Buy any Dip in Prologis Stock
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.